Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.49 – $2.12
54% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $28.3K | $31.6K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$28.3K | −$31.6K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $1.0M | $2.1M | $2.9M | $7.5M | $4.9M | $3.5M | $3.2M | $5.9M |
| Operating income | −$2.5M | −$7.7M | −$7.3M | −$14.1M | −$11.1M | −$7.7M | −$8.2M | −$11.1M |
| EBITDA | −$2.5M | −$7.7M | −$7.3M | −$14.3M | −$990 | −$153.1K | $27.1K | −$12.5M |
| Net income | −$2.5M | −$7.7M | −$7.2M | −$14.3M | −$11.4M | −$7.8M | −$8.2M | −$12.5M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -6.62 | -20.99 | -14.56 | -16.03 | -9.50 | -2.30 | -1.28 | -0.90 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-0.59 | $-0.59–$-0.59 | 1 |
| 2027 | $0 | $-0.70 | $-0.70–$-0.70 | 1 |
| 2028 | $0 | $-1.19 | $-1.19–$-1.19 | 1 |
| 2029 | $131M | $1.15 | $1.15–$1.15 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds HOTH.
No tracked institution reports a position in HOTH as of their last filing.
| Execution date | Ratio |
|---|---|
| 2022-10-26 | 1-for-25reverse |
No one on the platform has traded HOTH yet.
| $20M |
| — |
| ENTOEntero Therapeutics, Inc. | $2.85 | -5.00% | $14M | — |
| FBLGFibroBiologics, Inc. Common Stock | $0.79 | -3.78% | $2M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.